Investing.com -- Identity verification platform Incode Technologies Inc. is in preliminary discussions to raise between $150 million and $300 million from investors at a valuation of up to $3 billion, ...
Incode Technologies, Inc., the global leader in identity security and fraud prevention, today announced that iBeta PAD testing confirmed Incode’s face liveness technology achieves Level 3 Presentation ...
Liveness detection software from Incode has passed presentation attack detection (PAD) evaluations to iBeta’s Level 3 on both iOS and Android devices, making it the first liveness vendor with ...
Deepfakes are evolving and are no longer confined to misinformation campaigns or viral media manipulation. Most security teams already understand the deepfake problem; however, the more urgent shift ...
[OSEN = Kim Chaeyeon, reporter] Kim Jaejoong’s first produced boy group has officially thrown its hat into the ring in the music industry. Incode Entertainment (hereinafter Incode) confirmed the debut ...
Leaders like Goldman Sachs’ David Solomon say experience trumps everything in business—including brains. But Ricardo Amper, the founder and CEO of $1.25 billion software company Incode Technologies, ...
The OpenAge Initiative, the reusable age check system launched in November 2025 under the leadership of Singapore-based compliance firm k-ID, continues to attract new members in the biometrics and age ...
Deepfakes have evolved far beyond internet curiosities. Today, they are a potent tool for cybercriminals, enabling sophisticated fraud across onboarding, account recovery, partner verification and ...
Incode will contribute biometrics to improve the identity security and fraud protection of the U.S. government’s Login.gov platform. The face biometrics provider is a subcontractor to Diamond Capture ...
Incode Technologies has launched a new biometrics product to detect and block deepfakes and injection attacks, as agentic AI floods the tech landscape with new threat vectors. A release says Deepsight ...
GENinCode Plc (AIM: GENI), the Oxford based predictive genetics company focused on the prevention of coronary heart disease ("CHD" or "Heart Disease") and risk assessment of ovarian cancer, announces ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results